Desjardins, A., Vredenburgh, J. J., Gururangan, S., Peters, K. B., Friedman, A. H., Friedman, H., & Reardon, D. A. (2009). VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA: A PHASE I STUDY. In NEURO-ONCOLOGY (Vol. 11, pp. 634–634).

Desjardins, Annick, James J. Vredenburgh, Sridharan Gururangan, Katherine B. Peters, Allan H. Friedman, Henry Friedman, and David A. Reardon. “VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA: A PHASE I STUDY.” In NEURO-ONCOLOGY, 11:634–634, 2009.

Desjardins A, Vredenburgh JJ, Gururangan S, Peters KB, Friedman AH, Friedman H, et al. VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA: A PHASE I STUDY. In: NEURO-ONCOLOGY. 2009. p. 634–634.

Desjardins, Annick, et al. “VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA: A PHASE I STUDY.” NEURO-ONCOLOGY, vol. 11, no. 5, 2009, pp. 634–634.

Desjardins A, Vredenburgh JJ, Gururangan S, Peters KB, Friedman AH, Friedman H, Reardon DA. VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA: A PHASE I STUDY. NEURO-ONCOLOGY. 2009. p. 634–634.